Profile data is unavailable for this security.
About the company
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
- Revenue in USD (TTM)14.30bn
- Net income in USD-3.51bn
- Incorporated2019
- Employees30.00k
- LocationViatris Inc1000 Mylan BoulevardCANONSBURG 15317United StatesUSA
- Phone+1 (724) 514-1465
- Fax+1 (302) 655-5049
- Websitehttps://www.viatris.com/en
Mergers & acquisitions
| Acquired company | VTRS:NSQ since announced | Transaction value |
|---|---|---|
| Aculys Pharma Inc | 49.95% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin Pharmaceutical Inc | 3.22bn | 348.90m | 11.49bn | 3.22k | 33.53 | 1.89 | 26.82 | 3.57 | 1.78 | 1.78 | 16.57 | 31.65 | 0.4418 | 0.4726 | 4.11 | 1,000,079.00 | 4.79 | 3.09 | 5.28 | 3.46 | 81.43 | 78.42 | 10.83 | 8.18 | 3.50 | -- | 0.0893 | 0.00 | 12.87 | 11.60 | -18.26 | 138.08 | -4.20 | -- |
| Jazz Pharmaceuticals PLC | 4.16bn | -368.48m | 11.72bn | 2.80k | -- | 2.92 | 36.90 | 2.82 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| BridgeBio Pharma Inc | 502.08m | -724.93m | 12.70bn | 834.00 | -- | -- | -- | 25.29 | -3.78 | -3.78 | 2.62 | -10.71 | 0.5412 | -- | 6.97 | 602,009.60 | -79.01 | -76.52 | -105.26 | -96.54 | 95.82 | 96.16 | -145.98 | -340.73 | 2.68 | -2.17 | 4.29 | -- | 126.26 | 127.44 | -35.31 | -- | 4.99 | -- |
| Elanco Animal Health Inc | 4.72bn | -232.00m | 12.97bn | 9.40k | -- | 1.98 | 28.95 | 2.75 | -0.4848 | -0.4848 | 9.53 | 13.17 | 0.3631 | 1.28 | 5.62 | 501,595.80 | -1.79 | -2.26 | -2.01 | -2.53 | 54.99 | 55.59 | -4.92 | -7.41 | 1.08 | 1.15 | 0.3803 | -- | 6.22 | 7.59 | -168.64 | -- | -2.35 | -- |
| Neurocrine Biosciences Inc | 2.86bn | 478.60m | 13.29bn | 2.00k | 28.39 | 4.07 | 26.12 | 4.64 | 4.66 | 4.66 | 27.91 | 32.50 | 0.6851 | 0.8244 | 4.91 | 1,430,250.00 | 11.46 | 9.00 | 13.48 | 10.78 | 98.18 | 98.32 | 16.73 | 13.51 | 3.30 | -- | 0.00 | -- | 21.45 | 22.29 | 40.23 | 3.28 | 25.55 | -- |
| Viatris Inc | 14.30bn | -3.51bn | 18.08bn | 30.00k | -- | 1.23 | -- | 1.26 | -2.96 | -2.96 | 12.22 | 12.78 | 0.3634 | 2.20 | 5.44 | 476,663.30 | -8.93 | -1.35 | -10.68 | -1.61 | 39.55 | 40.86 | -24.58 | -4.18 | 0.8162 | 2.78 | 0.4948 | -- | -2.98 | 3.66 | -454.23 | -- | -7.35 | -- |
| Incyte Corp | 5.14bn | 1.29bn | 19.91bn | 2.84k | 15.62 | 3.84 | 14.43 | 3.87 | 6.40 | 6.40 | 25.61 | 26.04 | 0.8291 | 4.33 | 5.48 | 1,807,750.00 | 20.75 | 11.34 | 27.83 | 14.38 | 93.26 | 93.92 | 25.03 | 16.48 | 3.25 | -- | 0.0067 | 0.00 | 21.22 | 14.03 | 3,844.96 | -- | -20.67 | -- |
| Roivant Sciences Ltd | 13.31m | -809.24m | 20.11bn | 750.00 | -- | 4.67 | -- | 1,510.98 | -1.17 | -1.17 | 0.0193 | 6.02 | 0.0024 | -- | -- | 17,746.67 | -18.26 | 5.89 | -20.80 | 6.98 | 91.21 | 90.39 | -7,558.42 | 639.97 | -- | -- | 0.00 | 0.00 | -11.19 | -15.56 | -111.69 | -- | -1.32 | -- |
| Moderna Inc | 1.94bn | -2.82bn | 20.87bn | 4.70k | -- | 2.41 | -- | 10.74 | -7.26 | -7.26 | 5.00 | 21.95 | 0.1468 | 4.27 | 7.17 | 413,617.00 | -21.31 | 10.19 | -25.32 | 13.43 | 70.32 | 75.74 | -145.16 | 19.02 | 3.22 | -- | 0.0684 | 0.00 | -39.93 | 19.33 | 20.75 | -- | 24.53 | -- |
| United Therapeutics Corp | 3.18bn | 1.33bn | 22.52bn | 1.40k | 18.42 | 3.16 | 15.86 | 7.08 | 27.90 | 27.90 | 66.48 | 162.60 | 0.4176 | 2.25 | 10.11 | 2,273,357.00 | 17.51 | 14.75 | 19.14 | 16.07 | 87.92 | 89.79 | 41.94 | 39.28 | 6.28 | -- | 0.00 | 0.00 | 10.61 | 16.50 | 11.68 | 20.99 | 54.73 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 127.72m | 11.09% |
| Davis Selected Advisers LPas of 31 Dec 2025 | 78.18m | 6.79% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 77.29m | 6.71% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 62.10m | 5.39% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 55.31m | 4.80% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 37.37m | 3.25% |
| Geode Capital Management LLCas of 31 Dec 2025 | 31.11m | 2.70% |
| Columbia Management Investment Advisers LLCas of 31 Dec 2025 | 26.09m | 2.27% |
| Rubric Capital Management LPas of 31 Dec 2025 | 25.50m | 2.21% |
| Invesco Capital Management LLCas of 31 Dec 2025 | 22.48m | 1.95% |
